CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
budesonide +2 moredrug
Likely dose
terbutaline 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00989833
NCT00989833Phase 2Completed

A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol "As-needed", or Terbutaline "As-needed" or Regular Use of Budesonide + Terbutaline "As-needed", in Patients With Mild Intermittent Asthma

AstraZeneca·interventional·Posted Oct 6, 2009·Updated Aug 14, 2012

In Brief

A Phase 2 clinical trial evaluating budesonide, terbutaline, and 1 other intervention for Exercise Induced Asthma. Completed, enrolled 66 participants across 10 sites in 2 countries.

Detailed Summary

1. The primary objective of this study is: * To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma 2. The secondary objectives of this study are: * To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol as-needed compared to regular once daily use of budesonide plus terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma * To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and regular use of budesonide + terbutaline as-needed as terms of adverse event

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNorway, Sweden
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2009
Enrollment StartSep 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.7 years ago

Interventions

budesonidedrug

400 yg x 1

terbutalinedrug

0.4 mg as-needed

budesonide/formoteroldrug

160/4.5 yg as-needed